Benznidazole - Savant HWP/Humanigen

Drug Profile

Benznidazole - Savant HWP/Humanigen

Alternative Names: HWP-002; RO-71051

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Savant HWP
  • Developer Humanigen; Savant HWP
  • Class Acetamides; Antiprotozoals; Imidazoles
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chagas disease
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Chagas disease

Most Recent Events

  • 08 Aug 2017 Humanigen completes enrolment in clinical trial in Chagas' disease in USA
  • 07 Aug 2017 Humanigen intends to submit a New Drug Application (NDA) to the US FDA for the treatment of Chagas disease in first quarter of 2018
  • 07 Aug 2017 KaloBios Pharmaceuticals is now called Humanigen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top